Bringing more than 25 years of ophthalmic experience in retina, glaucoma, dry eye, and cornea/external disease, Julia has previously served in senior leadership roles at Aerie Pharmaceuticals, Allergan, Bausch & Lomb and Heidelberg Engineering. In these roles, Ms. Williams built and effectively led multidisciplinary teams across marketing, clinical and medical affairs functions in support of more than 15 successful product launches, including Lumigan® (bimatoprost), Combigan® (brimonidine tartrate/timolol)§, Ozurdex®(dexamethasone intravitreal implant)β, Xen® Gel Stentα, Rhopressa® (netarsudil)* and Rocklatan® (netarsudil/latanoprost).† She has designed and executed over 25clinical trials resulting in more than 40 authored or co-authored articles, book chapters and presentations in peer-reviewed ophthalmic literature.

Julia earned her Bachelor of Science in Cognitive Neuroscience and a master’s degree in Visual Psychophysics at the University of California San Diego and a micro MBA from the Rady School of Management

‍

^§Combigan^® and ^βOzurdex^® are registered trademarks of Allergan, Inc, an AbbVie company.

^αXen^® is a registered trademark of AqueSys, Inc., an AbbVie company.

^*Rhopressa^® and ^† Rocklatan^® are registered trademarks of Aerie Pharmaceuticals, Inc.

‍